| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 220.9 | 168.0 | 161.6 |
| Other income | 4.1 | 1.5 | 0.8 |
| Total income | 225.0 | 169.5 | 162.4 |
| Profit before exceptional items & tax | 15.7 | 5.2 | 11.5 |
| Exceptional items | 0.0 | 0.0 | 1.6 |
| Profit before tax | 15.7 | 5.2 | 9.9 |
| Net profit | 11.4 | 4.1 | 7.4 |
| Operating margin | 7.0% | 3.1% | 6.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +54.10% |
|---|---|
| Net profit, quarter on quarter | +178.00% |
| Revenue, year on year | +36.70% |
BSE results filing, BSE: 543828. Figures extracted from the filing.
Sudarshan Pharma Industries Ltd: key numbers
- Share price
- ₹38.50
- Market cap
- ₹926.5 Cr
- Revenue (annual)
- ₹703.1 Cr
- Net profit (annual)
- ₹23.30 Cr
- P/E (TTM)
- 39.8×Sector 37.5×
- Promoter holding
- 58.93%+1.54% QoQ
- FII holding
- 19.88%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudarshan Pharma Industries Ltd
All →Sudarshan Pharma Industries Annual General Meeting
Sudarshan Pharma Industries Ltd held its 18th Annual General Meeting on September 22, 2026. The meeting covered the adoption of financial statements and director re-appointment.
Sudarshan Pharma Industries Acquisition
Sudarshan Pharma stated its proposed 9.50% stake acquisition of Med Therapy Biotechnology Inc. remains under due diligence. Promoter acquisitions of 1.50% each are also pending.
Sudarshan Pharma Industries Share Pledge
Sudarshan Pharma Industries Ltd announced the release of a pledge of 20,00,000 equity shares held by its promoter, Mr. Hemal Mehta. This disclosure complies with SEBI regulations.
Sudarshan Pharma Industries Acquisition
Sudarshan Pharma Industries will acquire a 9.50% stake in MedTherapy Biotechnology Inc. for cash. Its promoters will separately acquire an additional 3% combined stake.
- Execution
- 31st March 2027
Sudarshan Pharma Industries Investor Presentation: Key Takeaways
Sudarshan Pharma Industries reports on its specialty chemicals and pharmaceutical business, highlighting the turnaround of Ratna Lifescience and strategic vertical integration into API manufacturing and branded generics.
Sudarshan Pharma Industries Q1 FY27 Results: Net Profit ₹5.6 Cr, Up 40.0% YoY
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹174.4 Cr (+20.0% YoY) and net profit of ₹5.6 Cr (+40.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹5.6 Cr · +40.0% YoY